Genentech -A PHASE III RANDOMIZED, VISUAL ASSESSOR MASKED, ACTIVE COMPARATOR, MULTICENTER EVALUATION OF THE EFFICACY, SAFETY AND PHARMACOKINETICS OF THE RANIBIZUMAB PORT DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF RANIBIZUMAB IN PATIENTS WITH nAMD

Administered By

Awarded By

Contributors

Start/End

  • December 20, 2018 - August 1, 2022